NCT06253546View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

June 12, 2025

Study Completion Date

June 12, 2025

Conditions
Schizophrenia
Interventions
DRUG

TV-44749

"Pharmaceutical form:~extended-release injectable suspension~Route of administration: subcutaneous injection"

DRUG

Oral Olanzapine

"Pharmaceutical form:~tablet~Route of administration:~oral"

Trial Locations (6)

100088

Teva Investigational Site 88049, Beijing

100191

Teva Investigational Site 88048, Beijing

200030

Teva Investigational Site 88046, Shanghai

430022

Teva Investigational Site 88050, Wuhan

510370

Teva Investigational Site 88047, Guangzhou

710061

Teva Investigational Site 88056, Xi'an

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT06253546 - Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia | Biotech Hunter | Biotech Hunter